Bohme T, Noory E, Brechtel K, et al. - Researchers performed a prospective, seven-center, single-arm, European Union trial (dates not provided). Treatment with a Viabahn endoprosthesis with a Propaten bioactive surface (Gore Medical, Newark, Del) was provided to a total of 71 patients with disabling claudication or rest pain with a ≥ 20-cm-long superficial femoral artery (SFA) and proximal popliteal artery (POP) occlusions. Per estimates using Kaplan-Meier analysis, the primary, assisted-primary, and secondary patency rates were 41%, 53%, and 97%, respectively, at 3 years. Overall findings suggest a low primary patency rate for heparin-bonded Viabahn stent grafts used to treat long SFA/POP occlusions. However, a high secondary patency rate was identified that appeared to be superior to other revascularization techniques.